Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Cantor Fitzgerald
Federal Trade Commission
US Department of Justice
Covington
Express Scripts

Generated: June 19, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ERIBULIN MESYLATE

« Back to Dashboard

Clinical Trials for Eribulin Mesylate

Trial ID Title Status Sponsor Phase Summary
NCT00047034 E7389 in Treating Patients With Advanced Solid Tumors Completed National Cancer Institute (NCI) Phase 1 Phase I trial to study the effectiveness of E7389 in treating patients who have advanced solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
NCT00334893 Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Completed National Cancer Institute (NCI) Phase 2 This phase II trial is studying how well eribulin mesylate works in treating patients with recurrent ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
NCT00337077 Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy Completed National Cancer Institute (NCI) Phase 2 This phase II trial is studying how well eribulin mesylate (E7389; Halichondrin B Analog) works in treating patients with metastatic prostate cancer that did not respond to hormone therapy. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
NCT00337103 E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes Active, not recruiting Eisai Inc. Phase 3 The purpose of this study is to compare E7389 versus capecitabine in patients with locally advanced or metastatic breast cancer who are refractory to the most recent chemotherapy. This is an open-label, randomized, two-parallel arm study. Patients will be randomized to receive either E7389 or capecitabine on a one-to-one ratio.
NCT00337129 S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed National Cancer Institute (NCI) Phase 2 RATIONALE: Drugs used in chemotherapy, such as E7389, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well E7389 works in treating patients with metastatic or recurrent head and neck cancer.
NCT00365157 Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction Active, not recruiting National Cancer Institute (NCI) Phase 1/Phase 2 This phase I/II trial studies the side effects and best dose of eribulin mesylate and to see how well it works in treating patients with cancer of the urothelium that has spread to nearby tissue or to other places in the body and kidney dysfunction. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Chemotherapy drugs may have different effects in patients who have changes in their kidney function.
Trial ID Title Status Sponsor Phase Summary

Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Eribulin Mesylate

Condition Name

Condition Name for Eribulin Mesylate
Intervention Trials
Breast Cancer 17
Metastatic Breast Cancer 11
Stage IV Urethral Cancer 3
Stage IV Breast Cancer 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Eribulin Mesylate
Intervention Trials
Breast Neoplasms 37
Carcinoma 5
Triple Negative Breast Neoplasms 4
Urethral Neoplasms 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Eribulin Mesylate

Trials by Country

Trials by Country for Eribulin Mesylate
Location Trials
United States 370
Japan 54
Canada 17
India 10
Spain 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Eribulin Mesylate
Location Trials
New York 21
California 20
Texas 19
Florida 18
Washington 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Eribulin Mesylate

Clinical Trial Phase

Clinical Trial Phase for Eribulin Mesylate
Clinical Trial Phase Trials
Phase 4 3
Phase 3 4
Phase 2 33
[disabled in preview] 28
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Eribulin Mesylate
Clinical Trial Phase Trials
Completed 23
Recruiting 20
Active, not recruiting 13
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Eribulin Mesylate

Sponsor Name

Sponsor Name for Eribulin Mesylate
Sponsor Trials
Eisai Inc. 27
National Cancer Institute (NCI) 18
Eisai Co., Ltd. 5
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Eribulin Mesylate
Sponsor Trials
Industry 50
Other 34
NIH 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Johnson and Johnson
Queensland Health
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.